Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood blood.2024025868.

https://doi.org/10.1182/blood.2024025868

Published: 2024

Includes: Supplemental data

Journal Articles

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Febe Smits, Kazem Nasserinejad, Mark-David Levin, Gert Jan Timmers, Esther G.M. De Waal, Josien C Regelink, Gerjo A. Velders, Matthijs Westerman, Nazik Durdu-Rayman, Suzanne Last-Koopmans, Roel JW van Kampen, Claudia A M Stege, Kaz Groen, Maarten R. Seefat, Monique C. Minnema, Pieter Sonneveld, Paula F Ypma, Niels W.C.J. van de Donk, Sonja Zweegman

Blood (2024) 144 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2024-203477

Published: 2024

Journal Articles

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Blood (2024) 144 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2024-208754

Published: 2024

Journal Articles

Bispecific Antibodies for Multiple Myeloma in the Real World: Lessons Learnt from a Nation-Wide Dutch Observational Registry

Marjolein Appelman, Rimke Oostvogels, Paulus A.F. Geerts, Laurens Franssen, Ellen van der Spek, Heleen de Lil, Cleo van Rooijen, Paula F Ypma, Wilfried Roeloffzen, Annemiek Broijl, Inger S. Nijhof, Ruth Wester

Blood (2024) 144 (Supplement 1): 7008.

https://doi.org/10.1182/blood-2024-193159

Published: 2024

Journal Articles

Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Konrad Van Der Zwet, Marjon H. Cnossen, Floor CJI Moenen, Saskia EM Schols, Paula F Ypma, Paul L. den Exter, Louise Hooimeijer, Michiel Coppens, Ron A.A. Mathôt, Anouk A.M.T. Donners, Alexander Janssen, Ilmar Kruis, Eduard J. Van Beers, Corien L. Eckhardt, Rolf T. Urbanus, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Kathelijn Fischer

Blood (2024) 144 (Supplement 1): 127.

https://doi.org/10.1182/blood-2024-193995

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Blood (2023) 142 (Supplement 1): 342.

https://doi.org/10.1182/blood-2023-180006

Published: 2023

Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 685.

https://doi.org/10.1182/blood-2023-177808

Published: 2023

Journal Articles

Monitoring Changes in Plasma Proteome in AML Patients Receiving Blood Transfusion Products

Diana Muñoz Sandoval, Eva Smit, Iris charlotte Kreft, Carmen van Der Zwaan, Pieter Van Der Meer, Jan Voorberg, Paula F Ypma, Jean-Louis Kerkhoffs, Maartje Van Den Biggelaar

Blood (2023) 142 (Supplement 1): 2665.

https://doi.org/10.1182/blood-2023-180853

Published: 2023

Journal Articles

Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients

Eva Kempers, Calvin B. van Kwawegen, Joke de Meris, Saskia E.M. Schols, Paula F. Ypma, Floor C.J.I. Moenen, Lize F.D. Van Vulpen, Michiel Coppens, Johanna G. van der Bom, Karin Fijnvandraat, Karina Meijer, Jeroen C.J. Eikenboom, Samantha C. Gouw, Frank W.G. Leebeek, Marieke J.H.A. Kruip

Blood (2022) 140 (Supplement 1): 1416–1417.

https://doi.org/10.1182/blood-2022-157537

Published: 2022

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137575

Published: 2020

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD

Blood (2018) 132 (Supplement 1): 596.

https://doi.org/10.1182/blood-2018-99-114668

Published: 2018

Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD

Blood (2018) 132 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2018-99-116920

Published: 2018

Journal Articles

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial

Blood (2018) 132 (2): 223–231.

https://doi.org/10.1182/blood-2018-02-831289

Published: 2018

Includes: Supplemental data

Journal Articles

Hemostatic Efficacy of Pathogen-Inactivated Buffy Coat-Derived Platelet Concentrates in Hemato-Oncological Patients: Outcomes of the Prepares Trial

Pieter F. Van Der Meer, PhD, Paula F Ypma, MD, Nan van Geloven, PhD, Rinie van Wordragen-Vlaswinkel, Anske van der Bom, MD PhD, Jean-Louis Kerkhoffs, MD PhD

Blood (2017) 130 (Supplement 1): 704.

https://doi.org/10.1182/blood.V130.Suppl_1.704.704

Published: 2017

Journal Articles

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Saskia K. Klein, MD PhD, Esther G.M. De Waal, MD, Corien M. Eeltink, RN, MA, ANP, Paula F. Ypma, MD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD PhD, Bea Tanis, MD PhD, Monique S. Slee-Valentijn, MD, Monique Minnema, Heleen Visser-Wisselaar, PhD, Claudia Stege, MD, Niels W.C.J. van de Donk, MD PhD, Kazem Nasserinejad, MA, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3305.

https://doi.org/10.1182/blood.V128.22.3305.3305

Published: 2016

Journal Articles

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Monique Minnema, Kazem Nasserinejad, MA, Bouke Hazenberg, MD PhD, Ute Hegenbart, Lucien Noens, MD PhD, Paula F. Ypma, MD, Sonja Zweegman, MD PhD, Lidwine Winnifred Tick, MD PhD, Annemiek Broijl, MD PhD, Harry R. Koene, MD PhD, Gerard M.J. Bos, MD PhD, Pieter Sonneveld, MD PhD, Stefan O. Schoenland, MD

Blood (2016) 128 (22): 4628.

https://doi.org/10.1182/blood.V128.22.4628.4628

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

NARROW

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Bispecific Antibodies for Multiple Myeloma in the Real World: Lessons Learnt from a Nation-Wide Dutch Observational Registry

Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Monitoring Changes in Plasma Proteome in AML Patients Receiving Blood Transfusion Products

Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial

Hemostatic Efficacy of Pathogen-Inactivated Buffy Coat-Derived Platelet Concentrates in Hemato-Oncological Patients: Outcomes of the Prepares Trial

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only